DPP-4 inhibitor teneligliptin improves insulin resistance and serum lipid profile in Japanese patients with type 2 diabetes

Drug Research

Volumn 65, Issue 10, 2014, Pages 532-534

  Kusunoki, M ^a   Sato, D ^b   Nakamura, T ^b   Oshida, Y ^c   Tsutsui, H ^d   Natsume, Y ^e   Tsutsumi, K ^f   Miyata, T ^g  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

^d TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f Okinaka Memorial Institute for Medical Research   (Japan)

^g Women's Medical Center of Sanno Medical Center   (Japan)

Author keywords

dipeptidyl peptidase 4 inhibitor; HDL cholesterol; insulin resistance; teneligliptin; triglyceride

Indexed keywords

ADIPONECTIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TENELIGLIPTIN; TRIACYLGLYCEROL; 3-(4-(4-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)PIPERAZIN-1-YL)PYRROLIDIN-2-YLCARBONYL)THIAZOLIDINE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PYRAZOLE DERIVATIVE; THIAZOLIDINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD GLUCOSE MONITORING; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; JAPANESE (PEOPLE); LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; MONOTHERAPY; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZOLES; THIAZOLIDINES; TREATMENT OUTCOME;

EID: 84924162326     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0034-1390419     Document Type: Article

References (23)

1. Kreymann B., Williams G., Ghatei M. A. et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet: 1987; 2 1300 1304
2. Edwards C. M., Todd J. F., Mahmoudi M. et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes: 1999; 48 86 93
3. Holst J. J., Deacon C. F. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes: 1998; 47 1663 1670
4. Lambeir A. M., Durinx C., Scharpé S. et al. Dipeptidyl-peptidase IV from bench to beside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci: 2003; 40 209 294
5. Kern M., Klöting N., Niessen H. G. et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One: 2012; 7 e38744
6. Nakaya K., Kubota N., Takamoto I. et al. Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet. Matabolism: 2013; 62 939 951
7. Fukuda-Tsuru S., Kakimoto T., Utsumi H. et al. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice. Eur J Pharmacol: 2014; 723 207 215
8. Shirakawa J., Fujii H., Ohnuma K. et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes: 2011; 60 1246 1257
9. Bomfeldt K. E., Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab: 2011; 14 575 585
10. Talayero B. G., Sacks F. M. The role of triglycerides in atherosclerosis. Curr Cardiol Rep: 2011; 13 544 552
11. Taskinen M. R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia: 2003; 46 733 749
12. Hanefeld M., Fischer S., Julius U. et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia: 1996; 39 1577 1583
13. Nakagami T. DECODA Study Group Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia: 2004; 47 385 394
14. Ervinna N., Mita T., Yasunari E. et al. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endicronology: 2013; 154 1260 1270
15. Kadowaki T., Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab: 2013; 15 810 818
16. Nonaka K., Kakikawa T., Sato A. et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract: 2008; 79 291 298
17. Shimasaki T., Masaki T., Mitsutomi K. et al. The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet induced obesity. PLoS One: 2013; 8 e63626
18. Masuda T., Fu Y., Eguchi A. et al. Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention. Am J Physiol Endocrinol Metab: 2014; 306 E388 E398
19. Moritoh Y., Takeuchi K., Asakawa T. et al. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β-cell function in db/db mice. Br J Pharmacol: 2009; 157 415 426
20. Kubota T., Kubota N., Kumagai H. et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab: 2011; 13 294 307
21. Nakagami H., Pang Z., Shimosato T. et al. The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome. Hypertens Res: 2014; 37 629 635
22. Monami M., Lamanna C., Desideri C. M. et al. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther: 2012; 29 14 25
23. Kusunoki M., Hara T., Tsutsumi K. et al. The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet. Diabetologia: 2000; 43 875 880